Inspection Record

Hospira Boulder, Inc. — FDA 483 Findings

US FDAInspected 2012-01-04Published 2021-04-21 6 findingsAseptic processing and sterility assuranceMaterial and supplier controlOther quality systemProcess validationLaboratory and QC controls

Inspectors Tara L Breckenridge · Richard L. Rutherford · Michele L. ObertThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Aseptic processing and sterility assurance

Procedures designed to prevent microbiological contamination ofdrug products purporting to be sterile are not established and written.

2Material and supplier control

Establishment ofthe reliability of the container supplier's report of analyses is deficient in that the test results are no t appropriately validated at appropriate intervals.

3Other quality system

Test devices are deficient in that instruments, apparatus, gauges, and recording devices not meeting established specifications are used.

4Aseptic processing and sterility assurance

Adequate exhaust systems or other systems to control contaminants are lacking in areas where air contamination occurs during production Specifically, Smoke studies are not representative of actual production practices which assess whether or not appropriate air changes and laminar air flow exists and can be maintained in a Grade A filling area.

5Process validation

There are no written procedures for production and process controls designed to assure that the drug products have the i dentity, strength, quality, and purity they purport or are represented to possess.

6Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate specifications and test procedures designed to assure that drug products conform to appropriate standards ofidentity, strength, quality and purity.

About this record

Extracted automatically from the document US FDA published on 2021-04-21. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

Hospira Boulder, Inc. company profile — full history US FDA documents, 2021 Go to Findings search